This agreement with Eli Lilly is another important part of our 2008 strategic plan to strengthen the company and build stockholder value ... We believe the royalty rate reduction and delay in certain clinical milestone payments for NGX426 will further enhance the commercial value of NGX426 and tezampanel.
















